Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(50%)

Results Posted

0%(0 trials)

Phase Distribution

Phase 3

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution1 total trials

Phase 3Large-scale testing

1(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Detailed Status

Enrolling by invitation1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 31 (100.0%)

Trials by Status

enrolling_by_invitation150%

completed150%

Recent Activity

1 active trials

Showing 2 of 2

enrolling_by_invitation

A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

NCT05708677

completedphase_3

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT04227106

Clinical Trials (2)

Showing 2 of 2 trials

NCT05708677

A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

Enrolling By Invitation

NCT04227106Phase 3

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Completed

All 2 trials loaded

Drug Details

Intervention Type: Biological
Total Trials: 2